Clinical Trials
32 trialsStudying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Hepatobiliary Tumors Tissue Samples Acquisition
Peking Union Medical College Hospital
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
OmicsWay Corp.
Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy
OmicsWay Corp.
Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia
European Organisation for Research and Treatment of Cancer - EORTC
SURTIME
European Organisation for Research and Treatment of Cancer - EORTC
Identification of Genes That Predict Local Recurrence in Samples From Patients With Breast Cancer Treated on NSABP-B-28
NSABP Foundation Inc
AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer
National Cancer Institute (NCI)
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
National Cancer Institute (NCI)
Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer
National Cancer Institute (NCI)
Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer
National Cancer Institute (NCI)
Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer
National Cancer Institute (NCI)
Dietary Phytoestrogens, Complementary and Alternative Medicine, and Lifestyle in Predicting Survival of Women With Breast Cancer
National Cancer Institute (NCI)
Study of Families With Melanoma
National Cancer Institute (NCI)
Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
National Cancer Institute (NCI)
CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide
National Cancer Institute (NCI)
Genetics of Women With Lobular Carcinoma in Situ of the Breast
National Cancer Institute (NCI)
Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma
National Cancer Institute (NCI)
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy
National Cancer Institute (NCI)
Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer
National Cancer Institute (NCI)
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer
National Cancer Institute (NCI)
GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Biomarkers in Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care Treatment
National Cancer Institute (NCI)
Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Liverpool Lung Project: Risk Factors and Genetic Markers in Healthy Participants and Patients With Lung Cancer
National Cancer Institute (NCI)
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182
National Cancer Institute (NCI)
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
National Cancer Institute (NCI)
Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
National Cancer Institute (NCI)